The volume of distribution of 5.8 l / kg. Since binding to plasma proteins is low (16%), interaction with other drugs is unlikely.
The absolute bioavailability is 48%. Amisulpride is metabolized slightly (about 4%, identified by two inactive metabolite cumulation amisulpride does not occur, and its pharmacokinetics remains unchanged after administration of repeated doses..
The anadrol pills amisulpride is approximately 12 hours after administration of an oral dose.
Amisulpride is excreted in the urine unchanged. Renal clearance is approximately 20 l / h or 330 ml / min.
rich carbohydrate diet (containing 68% fluids) significantly decreases the AUC (area under the concentration / time curve), time to maximum concentration and the very maximum concentration of amisulpride but changes in the pharmacokinetics after a fatty meal noted was not. However, the significance of these observations in clinical routine unknown.
liver failure. in view of the fact that the drug is poorly metabolized, there is no need to reduce the dose for patients with liver impairment.
Renal failure. Anadrol pills in patients with renal insufficiency is not changed, but the systemic clearance is reduced by a factor of 2.5 to 3. AUC amisulpride at low renal failure is doubled, and almost tenfold (see at a moderate failure. section Dosage and Administration). Practical experience, however, is limited and there are no results for use doses greater than 50 mg.
Amisulpride poorly dialyzed.
A limited number of pharmacokinetic data for the elderly (65 years) patients shows that after a single oral administration and higher than that of younger people. Data on the pharmacokinetics of the drug in the long-term treatment are not available.
Treatment of acute and chronic schizophrenia, accompanied by severe productive (eg, delusions, hallucinations, thought disorders) and / or negative (eg, affective flattening, lack of emotion and avoiding intercourse) disorders, including patients with predominantly negative symptoms.
- Hypersensitivity to the active ingredient of the drug or other components.
- Concomitant prolactin-dependent tumors, such as pituitary prolactinoma and breast cancer.
- Children’s age (14 years).
- Combination with the following medications that may contribute to the development of atrial fibrillation: quinidine, disopyramide, amiodarone, sotalol, as well as bepridilom, cisapride, sultopride, thioridazine, erythromycin, vincamine, halofantrine, pentamidine, sparfloxacin.
- Combination with levodopa. (See. “Interaction with other medicinal products” section).
With care – pregnancy, epilepsy, Parkinson’s disease, advanced age, renal insufficiency.
Dosing and Administration
In acute psychotic episodes recommended to use an oral dose of 400 to 800 mg per day. In some cases, the daily dose may be increased up to 1200 mg per day.
Dosages should be increased based on individual tolerance.
Safety doses greater than 1200 mg per day, has not sufficiently studied, so do not use them.
For patients with mixed negative anadrol pills and productive symptoms the dose should be selected so as to provide optimal control of productive symptoms.
Supportive care must be installed individually at minimum effective doses.
for patients with predominantly negative symptoms designation recommended oral dose of 50 to 300 mg per day. The selection of doses should be individualized.
In doses exceeding 400 mg per day, Amisulpride should be administered in 2 divided doses. Patients older vozvrasta: Amisulpride should be used with special caution because of the possible development of hypotension or excessive sedation. Renal failure: Excretion amisulpride through kidney. In renal insufficiency, the dose for patients with creatinine clearance should be reduced by half and 1/3 patients with anadrol pills.